Pomerantz LLP has filed a class action lawsuit against Anavex Life Sciences Corp. following the abrupt firing of its CEO for cause and the company's disclosure of a material weakness in financial controls. The CEO's termination announcement caused a 6.59% drop in Anavex's stock price, and the later admission of internal control issues led to another 6.35% decline. Investors who purchased Anavex securities during the class period have until November 30, 2026, to join the lawsuit or seek lead plaintiff status. This legal action highlights concerns about possible securities fraud and corporate mismanagement at Anavex.
Anavex Life Sciences Corp. is the subject of a class action lawsuit reminder amid recent corporate turmoil. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 03:41 WIB: out of 128 priced US health stocks, 29 rose and 99 fell. Notable movers include TXG at USD 71.79 with a 4.52% decline and 100% buy order activity, ERAS at USD 14.78 down 4.40% with 100% sell order activity, and NBIX at USD 135.50 down 4.15% with a nearly even buy/sell split.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Pomerantz LLP is investigating Kinross Gold Corporation for potential securities fraud following the company's announcement of a 2-3% reduction in its 2026 and 2027 gold production guidance due to operational and weather challenges at two smaller ass...
